Trabecular bone volume as measured at diagnosis of CML and following imatinib mesylate or α-interferon therapy
Patient details . | Trabecular bone volume (TBV)* . | ||||||
---|---|---|---|---|---|---|---|
At diagnosis . | After treatment . | Fold change . | |||||
Age . | Sex . | Time† . | TBV . | Range‡ . | TBV . | Range . | |
Imatinib treated patients (n = 17) | |||||||
32 | F | 22 | 8 | BN | 30 | AN | 3.7 |
37 | F | 17 | 25 | N | 26 | N | no change |
38 | M | 48 | 17 | N | 24 | N | 1.4 |
39 | M | 23 | 27 | N | 53 | AN | 2.0 |
41 | M | 18 | 22 | N | 36 | AN | 1.6 |
42 | M | 4 | 28 | BN | 30 | AN | 3.7 |
46 | M | 23 | 33 | AN | 18 | N | −0.5 |
53 | M | 33 | 16 | N | 50 | AN | 3.1 |
63 | M | 2 | 57 | BN | 90 | AN | 12.8 |
63 | M | 53 | 11 | N | 12 | N | no change |
65 | M | 35 | 11 | N | 27 | AN | 2.7 |
69 | M | 54 | 10 | BN | 19 | N | 1.9 |
70 | M | 19 | 14 | N | 42 | AN | 3.0 |
70 | M | 25 | 16 | N | 26 | AN | 1.6 |
52 | F | 23 | 24 | AN | 29 | AN | 1.2 |
54 | F | 62 | 18 | N | 37 | AN | 2.0 |
66 | F | 23 | 14 | N | 25 | AN | 1.8 |
P value§ | P = .005 | ||||||
α-interferon treated patients (n = 12) | |||||||
27 | M | 12 | 16 | BN | 23 | N | 1.4 |
31 | F | 18 | 11 | BN | 10 | BN | no change |
36 | F | 18 | 22 | BN | 19 | BN | no change |
45 | M | 45 | 14 | BN | 28 | AN | 2.0 |
47 | M | 12 | 11 | BN | 22 | N | 2.0 |
48 | M | 18 | 13 | BN | 26 | N | 2.0 |
55 | M | 45 | 15 | N | 21 | AN | 1.4 |
55 | M | 23 | 20 | N | 20 | N | no change |
65 | M | 31 | 28 | N | 16 | N | −0.6 |
67 | M | 18 | 26 | AN | 32 | N | 1.2 |
54 | F | 18 | 34 | AN | 24 | AN | −0.7 |
57 | F | 36 | 17 | N | 15 | N | no change |
P value‖ | P = .35 | ||||||
P value¶ | P = .36 |
Patient details . | Trabecular bone volume (TBV)* . | ||||||
---|---|---|---|---|---|---|---|
At diagnosis . | After treatment . | Fold change . | |||||
Age . | Sex . | Time† . | TBV . | Range‡ . | TBV . | Range . | |
Imatinib treated patients (n = 17) | |||||||
32 | F | 22 | 8 | BN | 30 | AN | 3.7 |
37 | F | 17 | 25 | N | 26 | N | no change |
38 | M | 48 | 17 | N | 24 | N | 1.4 |
39 | M | 23 | 27 | N | 53 | AN | 2.0 |
41 | M | 18 | 22 | N | 36 | AN | 1.6 |
42 | M | 4 | 28 | BN | 30 | AN | 3.7 |
46 | M | 23 | 33 | AN | 18 | N | −0.5 |
53 | M | 33 | 16 | N | 50 | AN | 3.1 |
63 | M | 2 | 57 | BN | 90 | AN | 12.8 |
63 | M | 53 | 11 | N | 12 | N | no change |
65 | M | 35 | 11 | N | 27 | AN | 2.7 |
69 | M | 54 | 10 | BN | 19 | N | 1.9 |
70 | M | 19 | 14 | N | 42 | AN | 3.0 |
70 | M | 25 | 16 | N | 26 | AN | 1.6 |
52 | F | 23 | 24 | AN | 29 | AN | 1.2 |
54 | F | 62 | 18 | N | 37 | AN | 2.0 |
66 | F | 23 | 14 | N | 25 | AN | 1.8 |
P value§ | P = .005 | ||||||
α-interferon treated patients (n = 12) | |||||||
27 | M | 12 | 16 | BN | 23 | N | 1.4 |
31 | F | 18 | 11 | BN | 10 | BN | no change |
36 | F | 18 | 22 | BN | 19 | BN | no change |
45 | M | 45 | 14 | BN | 28 | AN | 2.0 |
47 | M | 12 | 11 | BN | 22 | N | 2.0 |
48 | M | 18 | 13 | BN | 26 | N | 2.0 |
55 | M | 45 | 15 | N | 21 | AN | 1.4 |
55 | M | 23 | 20 | N | 20 | N | no change |
65 | M | 31 | 28 | N | 16 | N | −0.6 |
67 | M | 18 | 26 | AN | 32 | N | 1.2 |
54 | F | 18 | 34 | AN | 24 | AN | −0.7 |
57 | F | 36 | 17 | N | 15 | N | no change |
P value‖ | P = .35 | ||||||
P value¶ | P = .36 |
N indicates normal; AN, above normal; and BN, below normal.
Percent of the volume of the biopsy (bone and soft tissue) composed of trabecular bone.
Months of therapy at the time of the second bone biopsy.
Normal TBV ranges: adults younger than 50 years, 18% to 26%; men 50 years and older, 12% to 21%; women 50 years and older, 11% to 17%.18
P value describe the comparison of paired TBV data (before and after imatinib) using paired t test.
P value describe the comparison of paired TBV data (before and after α-interferon), for patients who achieved CHR and normocellular marrow after treatment (n=8), using paired t test.
P value describe the comparison of paired TBV data (before and after α-interferon, n=12) using paired t test.